← Oncology Approval Tracker

FDA DECISION ·

Kisqali / Kisqali Femara Co-Pack

ribociclib with endocrine therapy · Novartis

FDA approvalNew or expanded indicationBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adds men to the labeled HR-positive, HER2-negative advanced or metastatic breast cancer populations. Regimens include ribociclib with an aromatase inhibitor as initial endocrine therapy, or with fulvestrant initially or after progression on endocrine therapy in men or postmenopausal women. The co-pack contains letrozole.

LAMPGEN ANALYSIS

Why it matters

The label expands CDK4/6-based endocrine treatment eligibility to men with the specified subtype.

What research teams should watch

Capture sex, receptor results, endocrine history and the selected regimen when applying the revised label.

PRIMARY RECORDS

Sources